at time of diagnosis. In humans, stage I and II carcinomas, still confined to the primary site, are treated by surgical resection and adjuvant radiotherapy on indication, with a 5-year survival rate of 80%-90%. However, only 30%-50% of the patients present with this stage. For advanced (stage III-IV) carcinomas, the 5-year survival rate drops to approximately 45%. 10 Despite medical advancements, only limited improvements in survival have been achieved for humans with OSCC over the last decades and curative-intent surgery with ≥1 cm margins remains the most effective therapy for both humans and animals with OSCC. However, morbidity of surgical treatment is high for stage II or higher disease, urging the need for new treatment modalities for OSCC.
Treatment-related loss of tongue functions severely decreases the quality of life in both humans (speech, swallowing) and felines (feeding and grooming). In cats, the diagnosis of OSCC is commonly made in an advanced stage of the disease. Consequently, surgery is considered impossible or unethical in most cases. Surgery is only considered in a very select group of cats with small, localized tumours.
Effectiveness of palliative radiation protocols (consisting of 3-6 sessions of 6-10 Gy) and stereotactic radiation is low in felines with response rates of 39% or less and median overall survival (OS) times of 60 to 106 days. [11] [12] [13] More recently, several case series of accelerated hypofractionated radiotherapy protocols with or without chemotherapy and/or surgery suggest improved survival outcomes of 86 to 163 days. [14] [15] [16] [17] However, these are intensive treatment protocols that require multiple anaesthetic interventions and are accompanied by considerable costs and therapy-induced morbidity, with 91% overall complication rate and up to 78% grade 3 oral mucositis. 12, 14 Chemotherapy, tyrosine kinase inhibitors and immunotherapy alone have not achieved durable responses in macroscopic FOSCC. 18, 19 Holmium-166 ( 166 Ho) loaded microspheres (MS) are radioactive microspheres with a diameter of 10 to 30 μm that emit β-radiation (E β, max = 1.84 MeV, t 1/2 = 26.8 hours) which has a mean tissue penetration depth of 3.2 mm and a maximum tissue penetration of 8.7 mm. The combination of a localized intratumoral microsphere application with the short β-penetration depth enables a high, tumour-ablative radiationabsorbed dose in a single treatment, without causing extensive collateral damage to surrounding tissues. Furthermore, 166 Ho also emits a small fraction of γ radiation (6.71%, 80.6 keV) and can be visualized using nuclear Single-photon emission computed tomography (SPECT). In addition, 166 Ho can also be observed using Computed Tomography (CT) because of its high density, and with magnetic resonance imaging (MRI) because of its unique paramagnetic properties. [20] [21] [22] [23] These qualities provide an excellent opportunity for in vivo multimodality imaging, enabling treatment guidance and monitoring.
In human patients, 166 Ho MS are currently used in an intra-arterial transcatheter radio-embolization treatment of metastatic liver cancer. 22 Radio-embolization of small head and neck tumours is technically more demanding with the risk of unintended retrograde flow of particles into the carotid artery and into the brain that may result in serious complications including hemiparesis or even death. 24, 25 To overcome these obstacles, a direct intratumoral injection approach has been proposed for FOSCC. This concept of intratumoral injection of 166 Ho MS, also referred to as 166 Ho microbrachytherapy, has been investigated in laboratory animals and veterinary patients with spontaneous cancers. In these in vivo studies, renal cell carcinoma-bearing mice, Vx2 tumourbearing rabbits and feline patients with spontaneous liver tumours were treated with 166 Ho microbrachytherapy. In these studies, it was shown that extremely high tumour-absorbed doses could be attained (in excess of 6 times the absorbed dose that can be achieved with external beam radiotherapy) without major associated side effects. 26 166 Ho microbrachytherapy can therefore potentially be a safe and effective treatment option for both human and veterinary patients with head and neck cancer for whom no other treatment options are available. [26] [27] [28] The objective of this study was to prospectively evaluate safety and efficacy of 166 Ho microbrachytherapy in cats with spontaneous unresectable FOSCC. Therefore, a pilot study and subsequent dose reduction study were performed in feline patients.
2 | METHODS 
| Patient selection

| Diagnosis and staging
Baseline characteristics including breed, age, weight and tumour location were recorded. Each patient received a standardized staging procedure consisting of oral inspection, tumour inspection, palpation and manual evaluation of tumour size using 3-dimensional caliper measurements under general anaesthesia. Contrast-enhanced CT imaging of the primary tumour (head), locoregional lymph nodes (neck), thorax and abdomen was performed to determine tumour size, invasion in surrounding tissues, bone involvement and possible metastasis. The tumour volume was calculated using the 3 longest perpendicular diameters as measured on CT, assuming an ellipsoid shape; tumour volume = π/6 × length × width × height.
Any regional lymph node that was enlarged or abnormal on CT image was examined for metastasis by cytology of an ultrasoundguided fine needle aspiration biopsy. Tumour stage was determined according to the World Health Organization Tumor, Node, Metastasis (TNM) system for classification of oral tumours in domestic animals. 29 In addition, a complete blood count, blood biochemistry and urine analysis were performed to screen for subclinical disorders. 
| Patient preparation
| Microsphere preparation
The 166 Ho MS were prepared as previously described. 28, 30 After neutron activation, 166 Ho MS were suspended in a solution with Pluronic 
| Dosimetry
After selecting the planned tumour-absorbed dose for a certain tumour ("dose cohort", see later), the accompanying 166 Ho microbrachytherapy. As a result, the "treatment volume" was determined to be 1.5 × the tumour volume as measured on CT images. In addition, extra activity was ordered to account for anticipated losses of 166 Ho MS during suspension and syringe preparation, and during the administration procedure (residual 166 Ho MS remaining in the syringes after intratumoral injections and possible spillage outside of the tumour). 27 
| Pilot study
Initially, the treatment was started in a pilot setting (n = 5) using a relatively high 166 Ho activity, aiming for a tumour-absorbed dose of 400 to 800 Gy. This relatively high-tumour dose was chosen to overcome possible focal low-absorbed dose areas in the tumour because of inhomogeneous 166 Ho MS distribution and peritumoral deposition of 166 Ho MS. Based on previous pilot experiments, 26, 27 a "loss" of >50% of 166 Ho MS was expected during treatment due to possible leakage of 166 Ho MS out of the tumour needle tracts and premature settling and accumulation of 166 Ho MS in the syringe and needle dead space. A substantial additional loss of 166 Ho MS was anticipated during the process of microsphere suspension and preparation of the syringes for treatment. As a result, a double amount of radioactivity needed for the aimed tumour-absorbed dose was ordered for the pilot treatments. Subsequent analysis of the safety and observed efficacy in this pilot indicated that the applied procedures resulted in a higher than anticipated tumour-absorbed dose of >800 Gy. Therefore, the total anticipated loss of activity was adjusted to 50% of the activity needed for the intended treatment dose for further treatments. Furthermore, the study was continued as a minimal effective dose study to comply with the "As Low As Reasonably Achievable"
(ALARA) principles of radiation safety guidelines, as described in the next section.
| Dose reduction study
A dose reduction study approach was added to obtain data of possible dose-related side effects and minimal effective dose. Subsequent feline patients were randomly placed in 1 of 2 cohorts: a low dose cohort of 200 Gy (n = 4) and an intermediate dose cohort of 400 Gy (n = 4), to be compared with the initial high-dose cohort of >800 Gy of the pilot study (n = 5).
| Treatment procedure
The administration procedure was performed under general anaesthesia with endotracheal intubation in a dedicated radionuclide facility of our department. Patients were prepared by Povidone Iodine of the tumour location and oral cavity. To aid in a homogenous intratumoral-absorbed dose distribution and to prevent skipping parts of the tumour, the 166 Ho MS injections were orderly divided over predetermined equal tumour segments. The number of syringes was based on tumour volume. The injected volume was 0.3-0.6 mL per 1 mL tumour.
The activity of the prepared syringes was measured before the injection procedure. 166 Ho MS suspensions in the prefilled syringes for intratumoral injection were gently shaken before administration, to ensure a homogeneous suspension. The 166 
| Follow-up
A standard follow-up protocol was used for the first 6 months after treatment, consisting of follow-up examinations at 1 week, and at 1, 2, 4 and 6 months after discharge. During these examinations, tumour response was evaluated under general anaesthesia by oral examination and taking manual caliper measurements. A physical exam was performed to evaluate general patient condition, signs of tumour progression or metastasis, and possible radiation complications such as radiation ulcers and bone necrosis. If indicated, additional laboratory investigation or imaging was performed. A CT scan was performed at 1 or 2 months if residual tumour could not be accurately measured manually using calipers.
Adverse events were scored according to the Veterinary Radiation Therapy Oncology Group VRTOG. 32 Adverse events were classified by the investigational team according to the suspected relation to the treatment with 166 Ho microbrachytherapy into none, unlikely, possible, likely and definitive, based on causal relationship.
In addition to the planned 6-month follow-up protocol, all patients were reviewed until death, at any time in case of suspected side effects or recurrences. Long-term follow-up data of potential side effects, disease recurrence or metastasis, survival and cause of death were recorded for all patients.
| Response
Response to therapy was categorized using the following criteria: The data were registered in a dedicated database. The statistical analysis was conducted using SPSS 21. A power analysis was not performed. The significance level was set at P ≤ .05.
3 | RESULTS
| Patients
Thirteen feline patients with FOSCC were enrolled in the 166 Ho microbrachytherapy study between July 2009 and July 2015 with follow-up until February 2016 (Table 1 ). There were 8 male and 5 female patients, with a mean age of 14.3 AE 2.0 years and a mean body weight of 4.6 AE 1.1 kg. The tumours were located ventrally in the tongue/frenulum/sublingual (n = 10), the gingiva of the mandible (n = 1) or maxilla (n = 2). Eleven patients had clinical stage T2 disease, 
| Subsequent treatments
Additional laser ablation was performed in 5 cats: prior to 166 
| Response and survival
Eleven of 13 patients were discharged from the veterinary hospital and 250 days, respectively (log-rank P = .21).
| Complications and adverse events
None of the patients was lost to follow-up. During the study, 3 serious adverse events occurred. One was defined as "definitely related"
to the Ho MS could be a possible explanation for this complication. However, the calculated 99 mg 166 Ho MS that was injected during the 166 Ho microbrachytherapy procedure in this patient was divided over 5 syringes that were each used to inject 3 to 4 166 Ho MS depots. Therefore, accidental intravenous injection of large amounts of MS was not likely. Furthermore, 166 Ho activity was also found in the lung region after 166 Ho microbrachytherapy in one other patient in this study (Patient 13) without clinical signs during the follow-up period. Quantitative scintigraphy imaging, using SPECT-CT to enable correction of the scintigraphic images for local radiation attenuation from surrounding tissues, was not performed in this study. However, the fraction of activity in the lungs can be roughly estimated from the available scans using the recorded counts in the lung region and tumour region. This resulted in an estimated deposition of 30% of administered 166 A laser surgery-related complication occurred in 2 patients: a small unilateral rostral portion of the tongue, several centimetres rostral of the mid-ventral tumour location, became necrotic and was lost ( Figure 2 ). This complication developed shortly after laser surgery and was seemingly independent of 166 Ho microbrachytherapy in both patients. Loss of a small portion of the tongue was discovered 11 days after laser debulking, prior to 166 Ho microbrachytherapy in 
| DISCUSSION
To our knowledge, this is the first study on intratumoral treatment with radioactive microparticles in feline patients with OSCC. This study shows that cats with small unresectable OSCC can be curatively treated with a high dose of 166 Ho microbrachytherapy. Complete response was obtained in 27%, partial response in 36% and stable disease in 18% of the cats. Treatment-related side effects were mild in most animals; however, some serious adverse events occurred. A possible relation to 166 Ho microbrachytherapy will be investigated in further research and potential preventive measures proposed.
The outcome in this study compares favourably with currently available treatments for FOSCC with or without bone involvement in respect of clinical efficacy and complications: Several external beam palliative radiation schemes have been used in cats with 3 to 6 fractions of 6 to 10 Gy with only limited effect. [11] [12] [13] Radiation side effects were severe, resulting in a significantly diminished quality of life and early treatment termination: 43% of the patients did not complete the radiation protocol in 1 study. 11 In a large study of 54 animals, only 3 (6%) animals had a complete response, 30 (61%) had a partial response and 16 (33%) had stable disease at completion of treatment. The majority (49/54 animals, 91%) experienced complications compared with only 1 of 11 (9%) in the present 166 Ho microbrachytherapy study. 12 The median OS in these studies was 60, 92 and 111.5 days with a median local progression free survival of 43 days, respectively.
11-13
Accelerated hypofractionated protocols might be more effective with a median OS of 86 to 174 days with a LDPFS of 91 days in 12 animals. 14, 15 However, complications were still present in this twice-a-day radiation scheme resulting in grade 3 mucositis in 7 of 9 (78%) patients compared with 1 of 11 (9%) local radiation ulcer in the present 166 Ho microbrachytherapy study. Adding a systemic chemotherapeutic/radiosensitizer such as carboplatin or gemcitabine has been described to improve response rates, with 16 of 31 (52%) complete responders with an OS of 163 days. 14 Promising results have also been reported in 6 cats using an intensive multimodal treatment approach consisting of chemotherapy, accelerated hypofractionated radiation and surgery. This resulted in a complete response in 5 of 6 cats, and 3 cats alive with a followup of ≥1 year. 17 The OS of feline patients with OSCC treated with 166 Ho microbrachytherapy is similar to the OS reported in the studies with the A local side effect seen in this study was unilateral partial necrosis of the tip of the tongue (Figure 2 ). This complication occurred after laser surgery in 2 cats. Considering the unilateral tongue tip location and a clear demarcation region in the acute phase, it seemed to be the result of vascular compromise during laser surgery, causing ischemic necrosis distal to the tumour site. The fact that this complication occurred before 166 Ho microbrachytherapy in 1 patient and 3 weeks after 166 Ho microbrachytherapy in the other patient indi- Ho MS cannot be completely ruled out as cause of death. However, the estimated 21% of administered 166 Ho
MS that was detected in the lung region of patient 12 on scintigraphy images was less than the 30% detected in patient 13 that did not lead to any side effects. As a comparison, in the arterial 166 Ho MS radioembolization procedure that is commonly performed in humans with liver malignancies, a predetermined safety limit of "shunt-fraction" of MS (maximum of 20%) that may pass the liver and lodge in pulmonary vasculature is practiced. Activity in the lungs has been encountered during radio-embolization in humans without clinical signs. 22 Nevertheless, this unwanted systemic distribution of 166 probably have had benefit of intensive postoperative care and monitoring which was, however, not possible in the current treatment setting in the radionuclide facility and according to radiation safety guidelines. The other patient died during the 166 Ho microbrachytherapy procedure, most probably due to anaesthetic complications.
Especially, when considering that these cats are old, often have low body condition scores because of longer periods of reduced ability to eat and/or drink, periprocedural and anaesthetic care and monitoring should be optimally arranged. Considering the experimental nature of the 166 Ho microbrachytherapy and the radioactivity involved, anaesthesia and post-procedural care are challenging and more complicated compared with high-risk patients undergoing more common procedures. A well-trained team and constant awareness during the whole procedure are essential.
With a median-absorbed dose of 546 Gy, side effects were minimal. This is probably because of the short tissue penetration depth of the 166 Ho β-radiation with a mean of 3.2 mm and a maximum less than 9.0 mm. 34 The present data did not reveal a significant relation between absorbed dose and tumour response or a dose-dependent toxicity. This could be related to the small number of patients, or to the fact that all patients received a relatively high-absorbed dose compared with the 50 to 70 Gy of external beam radiation therapy.
However, the spatial distribution of 166 Ho microbrachytherapy over and around the tumour and therefore the distribution of the radiation-absorbed dose over the entire tumour is probably more important than the calculated total absorbed dose to a tumour. A suboptimal distribution of radioactive dose is more likely to occur in larger tumours and could, therefore, explain the significantly decreased local response rate in patients with larger tumours. This effect is probably larger than a possible dose-response relation, especially with the relatively low number of patients involved in the current study. Because of the limited tissue range of 166 Ho β-radiation, increasing the 166 Ho MS specific activity only has a limited effect on the dose distribution in case of a suboptimal 166 Ho MS distribution, stressing the importance of the 166 Ho microbrachytherapy strategy.
An important limitation of the 166 Ho microbrachytherapy procedure in the present study is the inability to monitor the intratumoralabsorbed dose distribution, especially in large tumours. The method of 166 Ho microbrachytherapy administration in predetermined tumour segments was aimed to create a proper intratumoral dose distribution. The resulting absorbed dose coverage of the entire tumour is, however, not known. The unique imaging properties of 166 Ho MS have recently been used to develop an MRI-based dosimetry method that is currently used to monitor dose distribution in humans after radio-embolization of the liver. 23 These developments are promising.
A real-time imaging-guided dosimetry technique could enable optimization of intratumoral radioactive dose distribution during 166 Ho microbrachytherapy, which may result in improved local response rates.
| CONCLUSION
The application of 166 Ho microbrachytherapy led to promising responses in feline patients with unresectable OSCC. The intratumoral microbrachytherapy as conducted in this cohort is an effective, minimally invasive treatment with minimal morbidity and limited side effects. Tumour volume was a significant predictor of response. Optimization of the injection procedure may improve spatial distribution of 166 Ho MS inside the tumour after injection, especially in large tumours, and result in an improved tumour response rate in future cases. Advantages of 166 Ho microbrachytherapy over current treatments using external beam radiation therapy in Feline OSCC patients warrant further investigation.
